Organogenesis Holdings (ORGO) EBIT (2016 - 2026)

Organogenesis Holdings has reported EBIT for 11 years, with the latest figure at -$51.0 million in Q2 2026.

• On a quarterly basis, EBIT fell 305.47% year-over-year to -$51.0 million in Q2 2026; TTM through Jun 2026 was -$35.9 million, a 56.89% decrease from a year earlier, with the FY2025 full-year figure at $44.7 million, up 3583.55% from the prior year.
• EBIT was -$51.0 million for Q2 2026 at Organogenesis Holdings, up from -$68.9 million in the prior quarter.
• The five-year high for EBIT was $63.3 million in Q4 2025, with the low at -$68.9 million in Q1 2026.
• Average EBIT over 5 years is -$2.3 million, with a median of $825500.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: EBIT plunged 3025.78% in 2023, then surged 905.28% in 2024.
• Over 5 years, EBIT stood at $8.7 million in 2022, then sank by 114.56% to -$1.3 million in 2023, then soared by 905.28% to $10.2 million in 2024, then jumped by 519.33% to $63.3 million in 2025, then slumped by 180.57% to -$51.0 million in 2026.
• The last three EBIT figures came in at -$51.0 million (Q2 2026), -$68.9 million (Q1 2026), and $63.3 million (Q4 2025), per Business Quant data.